Results from the regency trial assessing efficacy and safety of obinutuzumab in active lupus nephritis

Introduction: Obinutuzumab, a humanized type II anti-CD20 mono clonal antibody, is approved for B-cell malignancies. In the Phase II NOBILITY trial of patients with active lupus nephritis (LN;NCT02550652), study participants receiving obinutuzumab in addition to standard therapy were significantly m...

Full description

Autores:

Rovin, Brad
Furie, Richard
Garg, Jay

Tipo de recurso:

Fecha de publicación:

2025

Institución:

Universidad Simón Bolívar

Repositorio:

Repositorio Digital USB

Idioma:

eng

OAI Identifier:

oai:bonga.unisimon.edu.co:20.500.12442/16245

Acceso en línea:

https://hdl.handle.net/20.500.12442/16245
https://www.kireports.org/article/S2468-0249(24)03382-5/fulltext

Palabra clave:

Rights

openAccess

License

Attribution-NonCommercial-NoDerivs 3.0 United States